A Biotech Company Focused on Finding Transformative Treatments for the Most Serious Diseases

摘要

BIOTECH COMPANIES DO NOT GROW LIKEother businesses. In place of linear advances, there are exhilarating successes followed in quick succession by crushing failures. Vertex, a 30-year-old biotech company based in Boston, knows this journey well.In 2012, when current CEO Dr. Jeffrey Leiden joined the company, it was at a critical inflection point. That year, the company introduced a blockbuster drug to treat hepatitis C, only to be surpassed by a competitor and have the product taken off the market less than two years later. "[Back then] we were losing $300 million to $500 million every year, and the options for growth were limited," Leiden says. "We needed a way to refocus the company."